source
- Johnson & Johnson agrees to acquire eye-disease biotech Ollin Biosciences for up to $3.3 billionJohnson & Johnson announced Monday that it will purchase Ollin Biosciences, a biotech focused on eye diseases. The transaction is valued at up to $3.3 billion, representing one of the larger recen…
- Emerging biotech hubs like India could help lower global drug costs by scaling developmentThe article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…